Loading viewer...
investor_presentation
Format: PDF investor_presentation
Amadeus Jan-Sep 2018 Results November 7, 2018 © 2018 Amadeus IT Holding and its affiliates and subsidiaries
Jan-Sep 2018 Results
© 2018 Amadeus IT Holding and its affiliates and subsidiaries
_This presentation may contain certain statements which arenot purely historical facts, including statements about anticipated or
expected future revenue and earnings growth .Any forward -looking statements inthis presentation are based upon information
available toAmadeus onthe date ofthis presentation .Any forward -looking statements involve risks and uncertainties that could
cause actual events orresults todiffer materially from theevents orresults described intheforward -looking statements .Amadeus
undertakes noobligation topublicly update orrevise anyforward -looking statements, whether asaresult ofnew information, future
events orotherwise .Readers arecautioned nottoplace undue reliance onforward -looking statements .
_This presentation has tobeaccompanied byaverbal explanation .Asimple reading ofthis presentation without the appropriate
verbal explanation could give risetoapartial orincorrect understanding .
© 2018 Amadeus IT Group and its affiliates and subsidiaries© 2018 Amadeus IT Group and its affiliates and subsidiariesOperating Review
© 2018 Amadeus IT Group and its affiliates and subsidiariesProfitable expansion through September 2018
Note: Jan -Sep 2017 figures displayed throughout this presentation have been restated for IFRS 15 and 9, which we applied since J anuary 1, 2018 (see section 3.1 of January -September 2018 Management Review for
further details). Jan -Sep 2018 growth rates have been therefore calculated over 2017 restated figures.
1. We are early adopters of IFRS 16, which we applied since January 1, 2018. 2017 figures will not be restated for IFRS 16. In the first nine months of 2018, IFRS 16 had a positive €33.2 million impact on EBITDA. See
Varian Medical Systems Investor Presentation — January 2018
investor_presentationinvestor_presentation
10 Pages
Varian Medical Systems, Inc.
section 3.1 of January -September 2018 Management Review for further details .
2. Calculated using an acquisition price of $1,520 million and an estimated TravelClick ’ 2017 recurring EBITDA of $86 million. Translated to Euro using a USD/ €exchange rate of 1.1576 (source: ECB September 30,
2018). Net financial debt and last-twelve -month EBITDA based on the credit facility agreements’ definition._Revenue +4.6% (Exc. FX: 7.7%)
_EBITDA +8.6% (Exc. FX & IFRS161: high single -digit growth %)
•Negative FX impact on EBITDA
•Positive FX and IFRS 161 impact on costs
•Exc. FX and IFRS 161: small margin expansion
_Adjusted profit +5.1%
_Free Cash Flow +1.7%
•1.56x proforma for TravelClick acquisition2
Free CF9M 20185Recent business highlights
© 2018 Amadeus IT Group and its affiliates and subsidiariesAirline Distribution
_Renewed / signed 11 distribution agreements in Q3 2018,
including Aerolíneas Argentinas , Copa Airlines, Porter
Airlines and Norwegian .
Preview truncated — download the full document for the complete content.
presentation
investor_presentation
Snap
investor_presentation
Chinese Gamer